Effect Of Valsartan On N-Terminal Pro-Brain Natriuretic Peptide In Patient With Stable Chronic Heart Failure: Comparison With Enalapril

Background and Objectives: The plasma concentration of N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is a strong prognostic indicator for patients with heart failure (HF) across all stages of the condition. Several clinical trials have demonstrated convincingly that neurohormonal modulation on the renin angiotensin system (RAS) decreases plasma NT-proBNP level and results in favorable outcomes. But there are still limited comparative data on the neuro-hormonal modulatory effects of two RAS inhibitors: angiotensin converting enzyme inhibitor and angiotensin receptor blocker. Subjects and Methods: This study was a prospective, multi-center, randomized, open-label, controlled, and non-inferiority study involving 445 patients with left ventricular ejection fraction (LVEF) less than 45%. Patients were assigned to receive either valsartan (target dose of 160 mg bid) or enalapril (target dose of 10 mg bid) for 12 months. We compared plasma NT-pro-BNP, high sensitive C-reactive protein (hs-CRP) level and echocardiographic parameters before and after treatment with valsartan or enalapril. Results: The NT-pro-BNP and hs-CRP levels were significantly decreased after 12 months of treatment with valsartan and enalapril. The percentage change was similar between both groups. LVEF improved and left ventricular internal dimensions were decreased in both groups, and there were no significant differences between two groups. Conclusion: Valsartan is as effective on improving plasma NT-pro-BNP level as enalapril in patients with stable chronic HF.